FDA: Development of non-opioid analgesics for chronic pain, draft guidance for industry; availability
11 settembre 2025
Leggi
Breaking news
FDA: Continuous Glucose Monitor Apps Correction: Dexcom, Inc. issues correction for G7 Apps and ONE+ Apps due to a software design error that does not alert users of unexpected sensor failure
12 settembre 2025
Leggi
Global challenges in diabetes research and care: which way forward? An appraisal from the EASD Global Council
Giorgino F, Alzaid F, Pantea Stoian A, et al.
Diabetologia. Pub. online 10 Sep 2025.
Leggi
Early insulin degludec with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: a randomized controlled trial
Thammakosol K, Jantarapootirat M, Traiwanatham S, Sriphrapradang C
Diabetes Obes Metab. Pub. online 3 Sep 2025.
Leggi
Mobile app-based intervention and cardiovascular risk factors in patients with uncontrolled type 2 diabetes: a randomized clinical trial
Zhang PZ, Guo D, Liu CQ, et al.
JAMA Netw Open. Pub. online 2 Sep 2025.
Leggi
Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial
Ganeshalingam AA, Uhrenholt N, Arnfred S, et al.
JAMA Psychiatry. Pub. online 3 Sep 2025.
Leggi
Automated insulin delivery systems and glucose management in children and adolescents with type 1 diabetes: a systematic review and meta-analysis
de Visser HS, Waraich S, Chhabra M, et al.
JAMA Pediatr. Pub. online 8 Sep 2025.
Leggi
Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis
Kalayci A, Januzzi JL, Mitsunami M, et al.
Eur Heart J Cardiovasc Pharmacother. Pub. online 31 Aug 2025.
Leggi
FDA launches green list to protect americans from illegal imported GLP-1 drug ingredients
5 settembre 2025
Leggi
FDA’s concerns with unapproved GLP-1 drugs used for weight loss
5 settembre 2025
Leggi